Computer Science > Machine Learning
arXiv:2512.00586 (cs)
Abstract:This work presents the development and evaluation of an NLP-enabled probabilistic classifier designed to estimate the probability of technical and regulatory success (pTRS) for clinical trials in the field of neuroscience. While pharmaceutical R&D is plagued by high attrition rates and enormous costs, particularly within neuroscience, where success rates are below 10%, timely identification of promising programs can streamline resource allocation and reduce financial risk. Leveraging data from the this http URL database and success labels from the recently developed Clinical Trial Outcome dataset, the classifier extracts text-based…
Computer Science > Machine Learning
arXiv:2512.00586 (cs)
Abstract:This work presents the development and evaluation of an NLP-enabled probabilistic classifier designed to estimate the probability of technical and regulatory success (pTRS) for clinical trials in the field of neuroscience. While pharmaceutical R&D is plagued by high attrition rates and enormous costs, particularly within neuroscience, where success rates are below 10%, timely identification of promising programs can streamline resource allocation and reduce financial risk. Leveraging data from the this http URL database and success labels from the recently developed Clinical Trial Outcome dataset, the classifier extracts text-based clinical trial features using statistical NLP techniques. These features were integrated into several non-LLM frameworks (logistic regression, gradient boosting, and random forest) to generate calibrated probability scores. Model performance was assessed on a retrospective dataset of 101,145 completed clinical trials spanning 1976-2024, achieving an overall ROC-AUC of 0.64. An LLM-based predictive model was then built using BioBERT, a domain-specific language representation encoder. The BioBERT-based model achieved an overall ROC-AUC of 0.74 and a Brier Score of 0.185, indicating its predictions had, on average, 40% less squared error than would be observed using industry benchmarks. The BioBERT-based model also made trial outcome predictions that were superior to benchmark values 70% of the time overall. By integrating NLP-driven insights into drug development decision-making, this work aims to enhance strategic planning and optimize investment allocation in neuroscience programs.
| Comments: | Doctor of Engineering Praxis Dissertation, The George Washington University. 122 pages. Present affiliation: Iambic Therapeutics |
| Subjects: | Machine Learning (cs.LG); Computation and Language (cs.CL); Quantitative Methods (q-bio.QM) |
| Cite as: | arXiv:2512.00586 [cs.LG] |
| (or arXiv:2512.00586v1 [cs.LG] for this version) | |
| https://doi.org/10.48550/arXiv.2512.00586 arXiv-issued DOI via DataCite (pending registration) |
Submission history
From: Michael Doane [view email] [v1] Sat, 29 Nov 2025 18:40:42 UTC (2,991 KB)
Current browse context:
cs.LG
Change to browse by:
export BibTeX citation